Q2 2023

Source filing unavailable

Q2 2023 · —

Revenue—

Net Income

-$45.55M

N/M vs Q2 2022

EPS Diluted

-$0.26

N/M vs Q2 2022

Operating Income-$44,377,000N/M

Operating Cash Flowderived-$38,147,000—

Free Cash Flowderived

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2020	Q2 2019
Revenue	—	—	$293.00K	$338.00K
Net Income	-$45.55M	-$42.06M	-$32.05M	-$28.48M
EPS Diluted	-$0.26	-$0.46	-$0.62	-$0.65

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR